A Prospective Study of Gemcitabine and Carboplatin as First-Line Therapy in Advanced Non-Small Cell Lung Cancer: Toxicity of a Three- Versus a Four-Week Schedule

Gemcitabine and Carboplatin Treatment in Advanced NSCLC: A Retrospective Evaluation Including Elderly Patients

“…The results of this retrospective analysis suggest that this schedule seems to be active and well tolerated. Our data are comparable with those already published [9][10][11][12][13][14][15] . Unfortunately, the number of elderly patients is too small (n = 27) to demonstrate that the regimen is a good option in this patient setting.…”

“…The combination of gemcitabine and carboplatin has been used in the treatment of patients with advanced NSCLC in phase I and II trials, using 3-week as well 4week schedules [7][8][9][10][11][12][13][14] . The combination has been shown to be feasible and effective in several randomized trials 6,15 .…”

Gemcitabine and carboplatin in the treatment of locally advanced and metastatic non‐small cell lung cancer

“…However, the number of reductions and omissions of the day 15 gemcitabine dose was quite high in these trials. Several trials showed that a 3‐week regimen was better tolerated and equally effective in NSCLC 34–36 . Various doses of gemcitabine (1000 mg/m 2 , 1200 mg/m 2 and 1250 mg/m 2 ) have been used in the 21‐day regimen.…”

Gemcitabine and carboplatin in combination for the treatment of advanced, metastatic, non-small cell lung cancer

“…The question of 3-versus 4-weekly scheduling was addressed in two trials that comprised 58 previously untreated patients with unresectable advanced/metastatic NSCLC [28] . In the first trial 30 patients received carboplatin AUC 5 on day 1 and gemcitabine 1000 mg/m 2 on day 1, 8 every 21 days.…”